Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...
Business Insider1mon
Immuneering to present data from Phase 2a trial of IMM-1-104 in early January
PD and safety data from the Phase 1 portion of the company’s Phase 1/2a trial of IMM-6-415. Details of how to access the Investor Event will be provided in due course. Published first on TheFly ...
Yahoo Finance1mon
Why Is Immuneering Stock Trading Higher On Tuesday?
On Tuesday, Immuneering Corporation (NASDAQ:IMRX) revealed data updates from three pancreatic cancer arms of its ongoing Phase 2a trial of lead program IMM-1-104 and plans to expand the Phase 2a ...
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer - - Overall Response Rate (ORR) of 50%; ...
Hosted on MSN1mon
Immuneering expands lead program after favorable mid-stage data in pancreatic cancer
Immuneering Corporation (NASDAQ:IMRX) on Tuesday announced plans to add three new combination arms for its Phase 2a program for lead asset IMM-1-104 following favorable data against pancreatic cancer.
Benzinga.com1mon
Why Is Immuneering Stock Trading Higher On Tuesday?
IMM-1-104 with modified gemcitabine/nab-paclitaxel showed a 43% ORR and 86% disease control rate in first-line pancreatic cancer. IMM-1-104 monotherapy achieved ...